EMA
- Application: EMEA/H/C/004832
- Marketing authorisation holder: Daiichi Sankyo Europe GmbH
- Local brand name: Turalio
- Indication: Treatment of tenosynovial giant cell tumour.
- Pathway: orphan
- Status: rejected
🇪🇺 TURALIO™ in European Union
TURALIO™ (TURALIO™) regulatory status in European Union.
Marketing authorisation
TURALIO™ in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is TURALIO™ approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for TURALIO™ in European Union?
Daiichi Sankyo Europe GmbH holds the EU marketing authorisation.